A Phase 3 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 33rd largest by enrollment, is one of 13 that started in 2016, is one of 30 in phase 3, and was the 55th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 46th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2016, is one of 35 in phase 3, and was the 98th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic genotype 1 or 2 hepatitis C virus (HCV) infection who have previously failed a direct-acting antiviral (DAA)-containing regimen.
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
Drug: SOF/VEL · Drug: RBV
SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
Drug: SOF/VEL · Drug: RBV
Drug pages: Sofosbuvir · Velpatasvir
400/100 mg tablet administered orally once daily
Also known as: GS-7977/GS-5816, Epclusa®
Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Also known as: REBETOL®
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame: Up to 24 weeks
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
Time frame: Posttreatment Week 24
Percentage of Participants With HCV RNA < LLOQ at Week 1
Time frame: Week 1
Percentage of Participants With HCV RNA < LLOQ at Week 2
Time frame: Week 2
Percentage of Participants With HCV RNA < LLOQ at Week 3
Time frame: Week 3
Percentage of Participants With HCV RNA < LLOQ at Week 4
Time frame: Week 4
Percentage of Participants With HCV RNA < LLOQ at Week 5
Time frame: Week 5
Percentage of Participants With HCV RNA < LLOQ at Week 6
Time frame: Week 6
Percentage of Participants With HCV RNA < LLOQ at Week 8
Time frame: Week 8
Percentage of Participants With HCV RNA < LLOQ at Week 10
Time frame: Week 10
Percentage of Participants With HCV RNA < LLOQ at Week 12
Time frame: Week 12
Percentage of Participants With HCV RNA < LLOQ at Week 16
Time frame: Week 16
Percentage of Participants With HCV RNA < LLOQ at Week 20
Time frame: Week 20
Percentage of Participants With HCV RNA < LLOQ at Week 24
Time frame: Week 24
Change From Baseline in HCV RNA at Week 1
Time frame: Baseline; Week 1
Change From Baseline in HCV RNA at Week 2
Time frame: Baseline; Week 2
Change From Baseline in HCV RNA at Week 3
Time frame: Baseline; Week 3
Change From Baseline in HCV RNA at Week 4
Time frame: Baseline; Week 4
Change From Baseline in HCV RNA at Week 5
Time frame: Baseline; Week 5
Change From Baseline in HCV RNA at Week 6
Time frame: Baseline; Week 6
Change From Baseline in HCV RNA at Week 8
Time frame: Baseline; Week 8
Change From Baseline in HCV RNA at Week 10
Time frame: Baseline; Week 10
Change From Baseline in HCV RNA at Week 12
Time frame: Baseline; Week 12
Change From Baseline in HCV RNA at Week 16
Time frame: Baseline; Week 16
Change From Baseline in HCV RNA at Week 20
Time frame: Baseline; Week 20
Change From Baseline in HCV RNA at Week 24
Time frame: Baseline; Week 24
Percentage of Participants With Overall Virologic Failure
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
Time frame: Up to Posttreatment Week 24
Participants were enrolled at study sites in Japan. The first participant was screened on 25 July 2016. The last study visit occurred on 25 August 2017.
| Milestone | SOF/VEL FDC + RBV 12 Weeks | SOF/VEL FDC + RBV 24 Weeks |
|---|---|---|
| Started | 57 | 60 |
| Completed | 56 | 60 |
| Not completed | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) |
|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 85.1 (71.7 to 93.8) | 70.0 (34.8 to 93.3) | 97.9 (88.9 to 99.9) | 91.7 (61.5 to 99.8) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | 1.8 | 3.3 |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) | 86.0 (74.2 to 93.7) | 98.3 (91.1 to 100.0) |
SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) | 82.5 (70.1 to 91.3) | 96.7 (88.5 to 99.6) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 1 | 21.1 (11.4 to 33.9) | 25.0 (14.7 to 37.9) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 2 | 64.3 (50.4 to 76.6) | 70.0 (56.8 to 81.2) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 3 | 91.1 (80.4 to 97.0) | 90.0 (79.5 to 96.2) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 4 | 98.2 (90.4 to 100.0) | 98.3 (91.1 to 100.0) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 5 | 98.2 (90.4 to 100.0) | 98.3 (91.1 to 100.0) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 6 | 100.0 (93.6 to 100.0) | 98.3 (91.1 to 100.0) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 8 | 100.0 (93.6 to 100.0) | 100.0 (94.0 to 100.0) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 10 | 100.0 (93.6 to 100.0) | 100.0 (93.9 to 100.0) |
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 12 | 100.0 (93.6 to 100.0) | 100.0 (93.9 to 100.0) |
| percentage of participants | SOF/VEL+RBV 24 Weeks |
|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 16 | 100.0 (93.8 to 100.0) |
| percentage of participants | SOF/VEL+RBV 24 Weeks |
|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 20 | 100.0 (93.8 to 100.0) |
| percentage of participants | SOF/VEL+RBV 24 Weeks |
|---|---|
| Percentage of Participants With HCV RNA < LLOQ at Week 24 | 100.0 (93.8 to 100.0) |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 1 | -4.40 ± 0.640 | -4.36 ± 0.698 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 2 | -4.91 ± 0.510 | -4.89 ± 0.603 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 3 | -5.07 ± 0.506 | -5.02 ± 0.575 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 4 | -5.12 ± 0.486 | -5.04 ± 0.580 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 5 | -5.13 ± 0.487 | -5.05 ± 0.579 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 6 | -5.13 ± 0.492 | -5.05 ± 0.579 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 8 | -5.13 ± 0.492 | -5.06 ± 0.584 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 10 | -5.13 ± 0.492 | -5.06 ± 0.589 |
| log10 IU/mL | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Change From Baseline in HCV RNA at Week 12 | -5.13 ± 0.492 | -5.06 ± 0.589 |
| log10 IU/mL | SOF/VEL+RBV 24 Weeks |
|---|---|
| Change From Baseline in HCV RNA at Week 16 | -5.06 ± 0.594 |
| log10 IU/mL | SOF/VEL+RBV 24 Weeks |
|---|---|
| Change From Baseline in HCV RNA at Week 20 | -5.06 ± 0.594 |
| log10 IU/mL | SOF/VEL+RBV 24 Weeks |
|---|---|
| Change From Baseline in HCV RNA at Week 24 | -5.06 ± 0.594 |
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
| percentage of participants | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With Overall Virologic Failure | 15.8 | 3.3 |
Collected over Adverse Events and Serious Adverse Events: Up to 24 weeks + 30 days. All-Cause Mortality: Up to Posttreatment Week 24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF/VEL+RBV 12 Weeks | 0/57 (0%) | 0/57 (0%) | 43/57 (75.4%) |
| SOF/VEL+RBV 24 Weeks | 0/60 (0%) | 4/60 (6.7%) | 38/60 (63.3%) |
| Event | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 2/60 |
| PneumoniaInfections and infestations | 0/57 | 1/60 |
| Hepatic angiosarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 1/60 |
| Event | SOF/VEL+RBV 12 Weeks | SOF/VEL+RBV 24 Weeks |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 20/57 | 13/60 |
| AnaemiaBlood and lymphatic system disorders | 14/57 | 13/60 |
| HeadacheNervous system disorders | 11/57 | 2/60 |
| NauseaGastrointestinal disorders | 5/57 | 1/60 |
| StomatitisGastrointestinal disorders | 5/57 | 3/60 |
| Back painMusculoskeletal and connective tissue disorders | 4/57 | 1/60 |
| EczemaSkin and subcutaneous tissue disorders | 4/57 | 2/60 |
| GastroenteritisInfections and infestations | 0/57 | 4/60 |
| Dry skinSkin and subcutaneous tissue disorders | 0/57 | 4/60 |
| PruritusSkin and subcutaneous tissue disorders | 2/57 | 4/60 |
Safety Analysis Set: participants who received at least 1 dose of study drug
| Age, Continuous(years) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Mean | 63 ± 9.7 | 59 ± 15.7 | 64 ± 10.1 | 61 ± 7.2 | 63 ± 10.3 |
| Sex: Female, Male(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Female | 29 | 5 | 28 | 5 | 67 |
| Male | 18 | 5 | 20 | 7 | 50 |
| Race/Ethnicity, Customized(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Asian | 47 | 10 | 48 | 12 | 117 |
| Race/Ethnicity, Customized(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Not Hispanic or Latino | 47 | 10 | 48 | 12 | 117 |
| HCV genotype(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Genotype 1a | 2 | 0 | 1 | 0 | 3 |
| Genotype 1b | 45 | 0 | 47 | 0 | 92 |
| Genotype 2a/2c | 0 | 3 | 0 | 4 | 7 |
| Genotype 2b | 0 | 2 | 0 | 4 | 6 |
| Genotype 2 (No Confirmed Subtype) | 0 | 5 | 0 | 4 | 9 |
| IL28b Status(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| CC | 15 | 8 | 21 | 6 | 50 |
| CT | 28 | 1 | 20 | 6 | 55 |
| TT | 4 | 1 | 7 | 0 | 12 |
| HCV RNA (log10 IU/mL)(log10 IU/mL) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| Mean | 6.2 ± .47 | 6.6 ± .46 | 6.2 ± .51 | 6.2 ± .86 | 6.2 ± .54 |
| HCV RNA Category(Participants) | SOF/VEL+RBV 12 Weeks (GT1) | SOF/VEL+RBV 12 Weeks (GT2) | SOF/VEL+RBV 24 Weeks (GT1) | SOF/VEL+RBV 24 Weeks (GT2) | Total |
|---|---|---|---|---|---|
| < 800,000 IU/mL | 10 | 1 | 10 | 4 | 25 |
| ≥ 800,000 IU/mL | 37 | 9 | 38 | 8 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jul 2016 to primary completion in Jun 2017, 10 months.
Results were first posted in Jul 2018, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 10 months is below that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin